Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...
FiercePharma9h
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Monthly Prescribing Reference9h
Neoadjuvant/Adjuvant Opdivo Approved for Resectable NSCLC
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.